LogicBio Therapeutics: Potential breakthrough in the Treatment of Methylmalonic Acidemia (MMA).
LogicBio Therapeutics (NASDAQ: LOGC), a gene-editing company that uses its GeneRide technology platform to develop solutions for rare diseases in pediatric patients was recently awarded an Orphan Drug Designation (ODD) status for its LB-001 a recombinant adeno-associated viral vector with human methylmalonyl-COA mutase (MUT) gene...
